Treatment Strategy for Acromegaly
نویسندگان
چکیده
منابع مشابه
Current treatment guidelines for acromegaly.
Acromegaly, an indolent disorder of growth hormone (GH) hypersecretion is most typically caused by a somatotroph cell adenoma and may be treated by several modalities. Transsphenoidal surgical resection of micro-adenomas by experienced neurosurgeons results in biochemical normalization (postglucose GH <2 ng/mL, assay-dependent, age- and sex-matched IGF-I levels) in 70% of patients. However, ove...
متن کاملAcromegaly pathogenesis and treatment.
Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, tissue, and organ growth. High GH and IGF1 levels lead to comorbidities including arthritis, facial changes, prognathism, and glucose intolerance. If the condition is untreated, enhanced mortality due to cardiovascular, cerebrov...
متن کاملAcromegaly — Symptoms and Treatment
“Aging is not a beautiful thing.“ This sentence is heard by many patients of acromegaly at their visit to the doctor. The changes in the body are often not recognized or misclassified by medical professionals for a very long time. Often, a diagnosis is only reached after 9 or even 10 years. A visit to the endocrinologist can shed light on the condition, however. There is an excess production of...
متن کاملModern treatment of acromegaly.
Acromegaly is an endocrine disorder characterised by increased morbidity and mortality. It is usually caused by a growth hormone secreting pituitary adenoma and is manifested by a variety of clinical features. Surgery is usually the treatment of choice, however over the last few years, several new methods of treatment have been developed. A recent consensus on the targets for treatment has led ...
متن کاملPresurgical Octreotide: Treatment in Acromegaly
One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 tLg octreotide subcutaneously three times daily: for 3 to 6 weeks before surgery in 14 patients (group 1); and for 3 to 9 months in 41 and for 13 to 39 months in nine (n = 50, group 2), In 18 group 2 patients, the dose was increased step...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Neurosurgery
سال: 2015
ISSN: 0917-950X,2187-3100
DOI: 10.7887/jcns.24.521